2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Stavros V Konstantinides, Adam Torbicki, Giancarlo Agnelli...
https://pubmed.ncbi.nlm.nih.gov/25173341/Actively Recruiting
Led by Peking University First Hospital · Updated on 2025-07-31
1988
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are investigating how managing blood pressure during surgery and the use of dexamethasone may influence early and long-term outcomes in patients undergoing surgery for non-small cell lung cancer NSCLC. Surgery is the main treatment for NSCLC, but complications after surgery remain high and long-term survival is challenging. This study explores if avoiding low blood pressure during surgery and giving dexamethasone can reduce complications and improve survival. The trial compares four groups routine blood pressure management with placebo, routine blood pressure management with dexamethasone, targeted blood pressure management within 10% of baseline with placebo, and targeted blood pressure management with dexamethasone. Dexamethasone is given before anesthesia induction, and blood pressure is either managed routinely or tightly controlled throughout surgery. The study uses a 2 2 factorial randomized design to assess these interventions. Participants will be monitored for organ injury and complications within 5 days after surgery and followed for up to 5 years to assess overall survival and cancer-related outcomes. Researchers will collect data on intensive care unit admissions, mechanical ventilation duration, hospital stay length, and mortality rates. This comprehensive follow-up aims to evaluate both short-term safety and long-term survival benefits associated with the study interventions.
CONDITIONS
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
D
Dong-Xin Wang, MD, PhD
W
Wen-Wen Huang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University First Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo lung cancer surgery during which blood pressure is managed either routinely or within ±10% of baseline. They receive either dexamethasone or placebo before anesthesia induction to potentially reduce postoperative complications.
1 surgical procedure and immediate post-operative monitoring
Duration - Up to 30 days after surgery
Participants are monitored for organ injury, complications, and recovery outcomes up to 30 days after surgery.
Approximately 6 post-operative visits
Duration - Up to 5 years after surgery
Participants are followed to assess overall survival and cancer-related outcomes after surgery.
Annual visits or as scheduled for long-term outcome assessment
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
PREVENTION
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Stavros V Konstantinides, Adam Torbicki, Giancarlo Agnelli...
https://pubmed.ncbi.nlm.nih.gov/25173341/Alexander Emmert, Carmen Straube, Judith Buentzel...
https://pubmed.ncbi.nlm.nih.gov/28858083/A F M Scholz, C Oldroyd, K McCarthy...
https://pubmed.ncbi.nlm.nih.gov/26676760/Seong Yong Park, Jin Gu Lee, Jieun Kim...
https://pubmed.ncbi.nlm.nih.gov/23896023/Karim Asehnoune, Emmanuel Futier, Fanny Feuillet...
https://pubmed.ncbi.nlm.nih.gov/30904834/Vesna D Dinic, Milena Dragisa Stojanovic, Danica Markovic...
https://pubmed.ncbi.nlm.nih.gov/29459895/Jian Zhang, Chao Qin Chen, Xiu Zhen Lei...
https://pubmed.ncbi.nlm.nih.gov/23917675/E W Ely, R Margolin, J Francis...
https://pubmed.ncbi.nlm.nih.gov/11445689/John A Kellum, Norbert Lameire, KDIGO AKI Guideline Work Group
https://pubmed.ncbi.nlm.nih.gov/23394211/J A W Polderman, V Farhang-Razi, S van Dieren...
https://pubmed.ncbi.nlm.nih.gov/30821852/Peking University First Hospital
Lead Sponsor